Phyllis Tenkorang

Phyllis Tenkorang

Auto-generated profile, based on publicly available information

Phyllis Tenkorang

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in BMC Health Services Research
Verified
Journal Article
Open access
MIMartilord Ifeanyichi
Martilord Ifeanyichi
PTPhyllis Tenkorang
Phyllis Tenkorang
PRPedra Rabiee
Pedra Rabiee
AAAlshaheed Nasraldin Abdelhabeeb
Alshaheed Nasraldin Abdelhabeeb
MKMeskerem Kebede
Meskerem Kebede
RFRocco Friebel
Rocco Friebel
Introduction: The introduction of National Surgical, Obstetrics, and Anaesthesia Plans (NSOAPs) in Sub-Saharan Africa (SSA) aims to address the region’s significant gaps in access to surgical care. The financial implications of these plans, which are crucial for implementation and scaling, remain underexplored. This study presents a comparative analysis of the economic content of NSOAPs across ten SSA countries, highlighting financial strategies, costing, and proposed implementation frameworks. Methods: A mixed-methods policy content analysis was conducted. Data were collected from published documents, followed by a qualitative thematic analysis of economic components. Quantitative analysis focused on the comparison of total and per capita costs, adjusted for purchasing power parity (i.e., in International dollars [I$]), and aligned against socio-economic indicators. Results: There was significant variability in the economic content covered across the ten NSOAPs. Overall, most plans emphasised resource mobilisation and to a lesser extent financial protection, while purchasing was the most neglected. Nigeria and Tanzania provided the most comprehensive financing strategies, including innovative resource mobilisation, risk protection, and purchasing (at least implicitly); other countries like Rwanda and Madagascar lacked detailed financial protection and purchasing mechanisms. Total lifespan costs ranged from I$221 million (Senegal) to I$50.5 billion (Nigeria), with per capita costs varying widely. Annual costs as a percentage of Gross Domestic Product were modest, but in some countries, like Nigeria, implementation would require nearly 10% of the annual national budget. Involvement of (health) economics specialists and ministry of finance stakeholders was notably low, generally. Conclusion: NSOAPs represent an important policy tool for improving surgical care in SSA. However, inadequate economic planning and financing strategies present significant barriers to their implementation. Future plans should be developed through multi-disciplinary expertise and inter-sectoral engagement with a focus extending beyond resource mobilisation to encompass financial protection and purchasing to ensure sustainable investments in surgical care. Unbundling the plans into smaller, contextually prioritised packages may enhance their perceived financial feasibility and, consequently, their appeal to governments and funders.

4 September 2026 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
MIMartilord Ifeanyichi
Martilord Ifeanyichi
PTPhyllis Tenkorang
Phyllis Tenkorang
EMEsther Matey
Esther Matey
CEChizowa Okwuchukwu Ezeaku
Chizowa Okwuchukwu Ezeaku
OEOluwayemisi Ekor
Oluwayemisi Ekor
RFRocco Friebel
Rocco Friebel
Background: Surgical care is essential for achieving global health equity, yet low- and middle-income countries (LMICs) face major gaps in access and planning, partly due to limited evidence on the costs and resource requirements of surgical interventions. Understanding these costs is vital for designing efficient and equitable health systems. Methods: We conducted a systematic literature review (covering MEDLINE, EMBASE, Global Health, EconLit and grey literature) to identify studies reporting the costs of surgeries in LMICs from January 2000 to June 2023. Minor and major surgical procedures were considered, focusing on therapeutic procedures (excluding diagnostic interventions). Studies that clearly identified, quantified and costed hospital resources and services deployed in the provision of surgical care, and included at least two of the surgical production factors (ie, consumables, diagnostics, personnel, infrastructure and overhead) in the costing were included. Costs were standardised to 2023 International dollars (I$) for comparability. Results: A total of 74 studies from 29 countries met the inclusion criteria, with 210 cost estimates across 65 procedure groups. Costs varied widely: from I$1.54 for a caesarean section in Tanzania to I$618 098 for paediatric cataract surgery in Zambia. Full costing studies reported higher estimates than partial costing studies. Most studies (60%) originated from upper-middle-income countries, with limited data (10%) from low-income settings. Conclusion: This review provides a reference list of surgical procedure costs across LMICs, highlighting considerable cost variation by procedure, specialty and country. The findings underscore the need for better-quality, standardised cost data—especially from low-income countries—to inform national surgical plans, universal health coverage benefit packages and reimbursement policies.

30 September 2026 in International Journal of Health Policy and Management
Verified
Journal Article
Open access
PDF file
PTPhyllis Tenkorang
Phyllis Tenkorang
PWPhrutsamon Wongnak
Phrutsamon Wongnak
BKBenjaporn Kiatpakdee
Benjaporn Kiatpakdee
KPKittiphong Paiboonsukwong
Kittiphong Paiboonsukwong
NNNa’IMa Nasir
Na’IMa Nasir
Wirichada PanngumWirichada Panngum
Wirichada Panngum
Background: Thalassaemia is a genetic blood disorder endemic in Thailand. Management of severe thalassaemia utilises significant resources posing a substantial socio-economic burden; thus, prevention has been identified as a more sustainable approach to address thalassaemia. This study evaluated the cost-effectiveness and budget impact of various thalassaemia screening strategies in Thailand, including both pre-conception and post-conception approaches. Methods: A cost-effectiveness analysis (CEA), from the Thai healthcare payer’s perspective, was conducted using decision analytic modelling. Decision trees were used to estimate the incremental screening cost per severe thalassaemia birth averted for four main screening strategies compared to "no screening": post-conception screening (Strategy 1), pre-conception screening with targeted deoxyribonucleic acid (DNA) analysis (Strategy 2), pre-conception screening with universal DNA analysis (Strategy 3), and a combination of pre-conception and post-conception screening (Strategy 4). The cost-effectiveness threshold (CET) used was the lifetime cost of managing severe thalassaemia in Thailand. The annual budget impact of the upfront costs of implementing these strategies was also estimated. Results: Strategies 1, 2, and 4 were cost-saving compared to the threshold of the average lifetime cost of managing severe thalassaemia in Thailand, $21,017. Strategy 4 had the lowest screening cost of $6773 [$4522–$10 066] per severe thalassaemia birth averted. Strategy 2 cost $8977 [$5689–$13 956] per severe thalassaemia birth averted, and Strategy 1 cost $10 474 [$7121–$15 734] per severe thalassaemia birth averted. In contrast, Strategy 3 cost $57 692 [$33 240–$96 123] per severe thalassaemia birth averted and is not cost-saving. The annual budget impact of the upfront costs of implementing thalassaemia screening ranged from $1.30 million to $288.93 million, depending on the strategy adopted and uptake rates. Conclusion: Post-conception thalassaemia screening is cost-saving in Thailand. Combining pre-conception and post-conception screening strategies may offer even better value for money in the Thai context, but with a higher upfront cost of implementation.